• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, June 25, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Researchers focus on cell membranes to develop Alzheimer’s treatments

Bioengineer by Bioengineer
March 23, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ANN ARBOR–Thin parts of the cell membranes of neurons turn out to be particularly vulnerable to a protein that collects in the brain of people with Alzheimer's disease, according to a University of Michigan researcher.

The discovery could open an avenue for developing treatments for Alzheimer's disease that work within the cell's membrane.

The protein amyloid-beta builds up in the brains of people with Alzheimer's disease, ultimately aggregating into sticky clumps called plaque on the surface of neurons. U-M researcher Ayyalusamy Ramamoorthy, the Robert W. Parry Collegiate Professor of Chemistry and Biophysics, found that thinner parts of the neuronal membranes give access points to amyloid-beta, allowing the protein to puncture and kill those cells, and destroying the patient's ability to make and retain memory. This kind of build-up is also implicated in disorders such as Huntington's and type 2 diabetes.

These thin spots are composed of short fatty acid chains whereas the thicker parts of the membrane are composed of long fatty acid chains. The research team thinks that the formation of lipids with short chains–caused by aging or other physiological means that result in Alzheimer's–can promote cell death from the accumulation of amyloid-beta.

"We're trying to understand how components of the cell membrane and the physical and chemical properties of the lipid membrane would influence the aggregation of amyloid-beta by a variety of biophysical techniques," Ramamoorthy said. "The thickness of cell membranes is very important not only for Alzheimer's disease, but also for diabetes and other aging-related diseases."

The group investigated three types of lipids that varied in thickness. The thicker lipid membranes that were composed of longer fatty acid chains seemed to attract and promote the growth of plaque. The thinner membrane acted sometimes like a lipid and sometimes like a detergent, Ramamoorthy said.

The researchers found that the detergent-like fatty acid chains interact with the plaque, allowing that plaque to penetrate the cell membrane. A technique called phosphorus-31 nuclear magnetic resonance, which can reveal details at the atomic level within bilayers similar to the way a physician would use an MRI machine to look at tissues in the human body, allowed the researchers to examine how the collection of amyloid-beta in thinner membrane fragmented the cellular membrane.

The study was done in what's called a phospholipid bilayer, which consists of two layers of lipids. These layers are made up of hydrophobic, or water-hating, and hydrophilic, or water-loving phases, and look similar to a mixture of oil and water. This lipid bilayer replicates the cell membranes found in neurons. To measure amyloid-beta's toxicity, the researchers used neuronal cells.

"Many other labs are investigating the amyloid inhibition by small molecules in solution, but we are doing it in a membrane environment. From our study it is clear that the cell membrane is the hot spot where amyloid-beta becomes crazy," Ramamoorthy said. "The cell membrane is definitely not like a coffee filter that filters biological events–rather, it is the place where a plethora of biological actions happen."

Currently, Ramamoorthy's team is screening libraries of small molecular compounds that could target the aggregation of amyloid-beta within a person's cell membrane.

"These findings could be significant in the potential development of compounds to treat the aging-related diseases," he said.

###

This research was supported by the National Institutes of Health, the Protein Folding Initiative at U-M, the National Research Foundation of Korea and the University of Catania Grant FIR 2014. The study's co-authors include Kyle Korshavn, Cristina Satriano, Yuxi Lin, Rongchun Zhang, Mark Dulchavsky, Anirban Bhunia, Magdalena Ivanova, Young-Ho Lee, Carmelo La Rosa and Mi Hee Lim.

Media Contact

Morgan Sherburne
[email protected]
@umich

http://www.umich.edu/

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Tracking Lanthanide-Labeled Microplastics in Plants

June 25, 2026

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

June 25, 2026

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

June 25, 2026

Natural Hallucinogens: Evolution’s Ecological Tools, Not Mere Chemical Byproducts

June 25, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates

    92 shares
    Share 36 Tweet 23
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracking Lanthanide-Labeled Microplastics in Plants

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.